Brief: Clene's CNM-Au8 Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) Levels
15/06/2023 22:08
June 15 (Reuters) - Clene Inc. CLNN.O :
* CLENE'S CNM-AU8® SHOWS STATISTICALLY SIGNIFICANT
DIFFERENCE IN
PLASMA NEUROFILAMENT LIGHT (NFL) LEVELS IN HEALEY ALS PLATFORM
TRIAL
Source text for Eikon: ID:nGNX9cJ0S0
Further company coverage: CLNN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clene
See all newsClene Inc reports results for the quarter ended June 30 - Earnings Summary
Clene Q2 net loss widens on higher other expenses
Clene Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Clene Inc - Enters Second Amendment To Senior Secured Convertible Notes - SEC Filing
Clene Q1 loss widens on warrant liability issuance costs